TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

分组1 - TScan Therapeutics reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.27, and compared to a loss of $0.21 per share a year ago, indicating a negative earnings surprise of -7.41$0.67 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 53.59%, and this represents a significant decline from year-ago revenues of $7.21 million [2] - TScan Therapeutics shares have declined approximately 33.6% since the beginning of the year, contrasting with the S&P 500's decline of -1.8% [3] 分组2 - The earnings outlook for TScan Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.28 on revenues of$1.62 million, and for the current fiscal year at -$1.14 on revenues of$10.97 million [7] - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Another company in the same industry, Voyager Therapeutics, is expected to report a quarterly loss of $0.35 per share, reflecting a year-over-year change of -128$20.13 million, down 77.7% from the previous year [9][10]